Polyclonal and monoclonal antibodies have been raised against a fusion protein containing fl-galactosidase and part of the major capsid protein L1 of the human papillomavirus (HPV) type 16. The polyclonal antibodies cross-reacted with the L1 protein of several HPV types including HPV-1, -2, -6 and -11 when reacted with virusinfected tissue sections, and with HPV-6 and -18 L1 fusion proteins on Western blotting. Monoclonal antibodies against the L1 fusion protein of HPV-16 reacted only with HPV-16 L1 fusion proteins on Western blots and with HPV-16-containing biopsy sections as assessed by in situ DNA-DNA hybridization. These antibodies did not detect HPV-6 L1 protein after Western blotting or in HPV-6-infected tissue sections, although one did react with an HPV-18 fusion protein after Western blotting. The monoclonal antibodies were able to detect HPV-16 antigens in routine formaldehydefixed, wax-embedded sections of cervical intraepithelial neoplasia sections. HPV-16 L1 proteins were seen in one-third of biopsies that were positive using the polyclonal cross-reacting antisera. Polyclonal antibodies to fusion proteins containing part of the minor capsid protein L2 of HPV-6 or -16 appeared to be more type-specific as no crossreactivity was seen when these antibodies were reacted with HPV-1-and -2-infected tissue sections.
INTRODUCTION
Certain human papillomaviruses (HPV) are associated with premalignant and malignant disease of the genito-urinary tract, in particular carcinoma of the cervix (Dtirst et al., 1983; Boshart et al., 1984; McCance et al., 1985) . HPV types 6 and 11 are associated with benign condylomata acuminata (genital warts) (Gissmann et al., 1983; McCance et al., 1986) and low grade cervical intraepithelial neoplasia (CIN) (McCance et al., 1985) which is a premalignant lesion localized in the transformation zone of the cervix. HPV-16 and -18 (Dfirst et al., 1983; Boshart et al., 1984) are the commonest viruses associated with all grades of CIN (grades I to III) and with malignant carcinoma of the cervix. In addition HPV-16 has been shown to be associated with progression of mild CIN (grade I) to severe CIN (grade III) (Campion et al., 1986) .
This association of HPV with cervical disease has been confirmed by a number of groups using DNA-DNA hybridization to detect the viral genome in abnormal cells. Type-specific antibodies have not been produced because these viruses as a group do not replicate and produce infectious virus in cell cultures, so quantities of virus particles sufficient for antibody production are not available. Antibodies raised against detergent-disrupted bovine papillomavirus type 1 (BPV-1) have been used to detect H PV antigens in tissues but these antibodies cross-react with most animal and human papillomaviruses and are not type-specific (Jenkins et al., 1986) . There is a need for type-specific sera for diagnostic purposes since, in particular, HPV-16 is associated with progressive disease. I  I  I  I  I  I  I  I   1000  2000  3000  4000  5000  6000  7000  7905 Base pairs Antisera raised against a peptide contained in the major capsid protein (L1) as well as to an L1 fusion protein of HPV-16 have been shown not to cross-react with the L1 of HPV-6 on Western blots (Banks et al., 1987) . Antisera against the peptide of L1 was tested on tissue sections and shown not to react.
We report here that polyclonal rabbit antisera raised against part of the major capsid protein of L1 of both HPV-6 and -16 cross-react on sections of tissue infected with a number of HPV types, but that monoclonal antibodies raised against HPV-16 L1 are type-specific and detect capsid antigen in routine formaldehyde-fixed, wax-embedded tissue and may be used diagnostically to detect HPV-16-infected lesions. antigens. Since the virus cannot be propagated in vitro, antigens for animal inoculations were produced as fusion proteins containing ,8-galactosidase and the L1 and L2 regions of HPV-6 and -16.
METHODS

Construction and isolation of fusion proteins containing
A 586 bp fragment of DNA from the L1 gene of HPV-6 (139K, L1/6) and a 637 bp fragment of L1 of HPV-16 (141K, L1/16) were cloned at the BamHI and Pstl sites of the vectors pEX1, -2 and -3 (Fig, 1) (Stanley & Luzio, 1984) . Similarly a 483 bp fragment of L2 of HPV-6 (143K, L2/6) and a 686 bp fragment of L2 of HPV-16 (143K, L2/16) were cloned into pEX1, -2 and -3 (Fig. 1) . These vectors were used to transform Escherichia coil strain pop 2316 and fusion proteins were produced when the bacteria were transferred to 42 °C from their normal growth temperature of 28 °C. Cells containing the pEX1 vector containing the in-frame fragments were analysed by PAGE with Coomassie Brilliant Blue staining. These vectors were then expressed in E. coli pop 2316 and large scale protein extracts were purified by running them through a Sepharose 4B-CL column as described by Doorbar et al. (1986) . It was possible to collect 20 to 50 mg of fusion protein of 95% purity by this method. Spleen cell fusions. An intravenous challenge of fusion protein (2gg Lt of HPV-16) was given 3 days before fusion. The spleen was removed aseptically and a single-ceil suspension made in RPMI culture medium (Gibco).
These spleen cells were fused with the mouse myeloma NSI/1 .Ag4.1 ( K6hler et al., 1976 ) at a 2:1 spleen to myeloma cell ratio in the presence of 50~ polyethylene glycol (M~ 1400; BDH) for 90 s, then diluted in RPMI medium containing 10~ foetal calf serum and HAT (0-96 ~tM-hypoxanthine, 0.16 gM-thymidine, 0.36 gMaminopterin) before plating out into 24-well Linbro plates at 2 x 106 cells/well containing l0 s spleen cells/well as feeder cells.
Analysis of antibody reactivities
Polyclonal antisera. Polyclonal antisera against the fusion proteins L1/6 and L1/16 were tested for homologous and heterologous activity on Western blots (Towbin et al., 1979) . All sera were first absorbed with induced extracts from untransformed bacteria.
Monoclonal antibody screening. Tissue culture medium from wells containing hybrids was tested for antibody specificity against the fusion protein from HPV-16 (L1/16) and control fusion protein from HPV-1 E4 (a gift from Dr J. Doorbar), L1/6 and/~-galactosidase in a solid phase radioimmunoassay using affinity-purified ~zSI-labelled rabbit anti-mouse IgG (sp.act. 750 MBq/mg; laboratory prepared) as the detection system. Hybrids secreting antibody specific for HPV-16 L1 fusion protein were cloned twice by the doubling dilution method to 1 cell/well in microtitre plates (containing feeder cells) and then grown up in 75 cm fiat-bottomed flasks (Nunc).
Immunoperoxidase staining of tissue sections. Formol sublimate-fixed (colposcopy biopsies were fixed with formyl mercury) tissue embedded in paraffin wax was sectioned and then dewaxed in xylene, washed with alcohol and hydrated. These tissue sections were incubated in 0-5~ iodine (in 70~ alcohol) for 5 min followed by treatment with 5 ~ sodium thiosulphate to remove the mercury. Immunoperoxidase staining was carried out using the ABC complex (Jenkins et al., 1986) .
In situ hybridization. DNA-DNA in situ hybridization was carried out as previously described (Collins et al., 1988) . Briefly, linear HPV-6 and HPV-16 DNA was digested with PstI and labelled with [35S]dCTP by nick translation. Formaldehyde-fixed and wax-embedded tissue sections were dewaxed with xylene, rehydrated and treated with 2 mg/ml proteinase K before the probe and tissue DNA were denatured at 95 °C in hybridization solution. Hybridization was carried out at Tm-25 °C and subsequent washing at T m -17 °C. Slides were coated with Ilford K2 emulsion and exposed for 3 to 5 days.
RESULTS
Reactivity of polyclonal antibodies raised against HPV fusion proteins
To test the cross-reactivity of polyclonal antiserum raised against L1/16, serum was tested against tryptophan fusion proteins from p6L1HX l, p 16L1BN 1 and p 18L 1XX 1 containing the L 1 of HPV-6, -16 and -18, respectively, and on sections infected with either H PV-6 or -16. When tested by Western blotting (data not shown), the antiserum cross-reacted with the L1 protein of the other HPV types.
Sections of CIN lesions and condylomata (genital warts), known to contain HPV-16 and HPV-6 respectively by DNA-DNA in situ hybridization, were reacted with rabbit antiserum against L1/16 followed by peroxidase-conjugated anti-rabbit secondary antibodies. Biopsy sections containing HPV-6 DNA detected by in situ hybridization (Fig. 2a) were positive confirming the cross-reactivity of polyclonal antisera raised against L1 of HPV-16 (Fig. 2b) . As expected the homologous reaction to HPV-16 was positive. In addition anti-L1/16 polyclonal antibodies reacted with HPV-11-containing sections (data not shown), and were able to detect L1 proteins in HPV-I-and -2-containing cutaneous warts (J. Doorbar, personal communication) . These data therefore show that polyclonal antibodies to L1/16 are not type-specific even between genital isolates but cross-react across a broad range of HPVs from different anatomical sites. Antibodies raised against the L2 capsid protein of both HPV-6 and -16 reacted very faintly with biopsy sections containing the homologous virus. The lack of reactivity may be due to low levels of expression of the L2 protein since it is a minor capsid component. Alternatively, L2 may be sensitive to formaldehyde fixation, since frozen sections of cutaneous warts infected with HPV-1 or -2 contain abundant L2 proteins. When these HPV-1-and -2-infected sections were reacted with anti-L2/6 or L2/16 antibodies no cross-reactivity was detected (J. Doorbar, personal communication). These results suggest that antibodies against L2 proteins may have a more limited cross-reactivity than anti-L1 antibodies.
Reactivity of monoclonal antibodies raised against L1/16
Because of the cross-reactivity of polyclonal antisera, monoclonal antibodies were produced as possible type-specific reagents.
Nine hybridoma cell lines which secreted mouse monoclonal antibodies specific for the fusion protein constructed from the L1 region of HPV-16 were isolated. Type specificity was tested by Western blot analysis Fig. 3 shows the reaction of one of the selected monoclonal antibodies, ID6, with the flgalactosidase fusion protein from L1 of HPV-16 (Ll/16), but no reactivity with L1/6 or flgalactosidase. On further testing seven of nine monoclonal antibodies reacted with HPV-16 fusion proteins only while two others, IC6 and 4D4, also reacted with the L1 of HPV-6 and -18. Fig. 4 shows the reactivity of ID6 to the tryptophan L 1 fusion proteins of HPV-6, -16 and -18 and demonstrates the HPV-16 specificity.
Tissue sections
Sections of biopsies taken from C I N lesions showed HPV-16 type specificity (Table 1) (Fig. 5 a) . Sequential sections from these biopsies, on in situ (Fig. 5b) . This biopsy did not contain HPV-6 DNA. By the same technique sections of CIN which showed the presence of HPV-6 in high copy numbers using an HPV-6 probe ( Fig. 5c ) did not bind any antibody (Fig. 5d ). These sections did not contain HPV-16 DNA. HPV structural antigens, however, were present in these sections as seen when they were reacted with the polyclonal antibodies. Monoclonal antibodies 5A4, 3D1 and ID6 cross-reacted with HPV-2-containing sections (J. Doorbar, personal communication), but not with HPV-1, -6 or -11. The fact that on Western blotting monoclonal antibodies IC6 and 4D4 reacted with the HPV-6 fusion protein, but did not react with HPV-6 infected tissue sections ( Table 1 ), suggests that these antibodies either interact with linear epitopes that are hidden in the tissue sections where the virus capsid is assembling or that the epitopes are destroyed by formaldehyde fixation. The monoclonal antibodies were of the IgGl class and peptide mapping showed that they reacted with either of two regions in the fusion protein (J. Cason et al., unpublished data) .
Detection of HP V-16 in routine biopsy sections using monoclonal antibody 5A4
Biopsies (32) of various grades of CIN which were positive for HPV capsid antigens when tested with anti-L1/16 polyclonal antibodies were reacted with the 5A4 monoclonal antibody. Ten of the 32 biopsies were positive for the HPV-16 L1 antigen. All were confirmed HPV-16-positive by DNA-DNA in situ hybridization.
DISCUSSION
Certain HPV types are associated with genital cancer, especially carcinoma of the cervix. HPV-6 and -11 are associated with benign genital warts (condylomata acuminata) and low grade CIN (Gissmann et al., 1983) while HPV-16 and -18 are found infrequently in benign lesions but are present in all grades of CIN and in malignant disease of the cervix and penis (D/irst et al., 1983; Boshart et al., 1984; McCance, 1986) . HPV is at present typed by genome homology using DNA-DNA hybridization, because the lack of an in vitro cell culture system means that sufficient amounts of viral antigens are not available for serological comparisons.
Since various HPV types are associated with genital lesions of different malignant potential it is important to differentiate between types. However, DNA-DNA hybridization, which at present is the only available method for HPV typing, is technically too difficult and timeconsuming to be considered as a diagnostic tool. Serology would be a simpler method, but even if HPV antigens were produced it is known that the major capsid protein (L1) of all HPV types so far sequenced is highly conserved at the DNA and amino acid level (Baker, 1987) .
In this study we have produced polyclonal and monoclonal antibodies to fusion proteins of flgalactosidase containing portions of the proteins making up the major L1 and minor L2 capsid proteins of HPV-6 and -16. The rabbit polyclonal antibodies raised to the fusion proteins containing the L1 of either HPV-6 or -16 cross-react strongly on tissue sections infected with other HPV types such as H PV-1, -2 and -11. On Western blotting anti-L 1/16 antibodies crossreact with heterologous antigens, but not with the same strength as the homologous reaction. This suggests that secondary and tertiary structures are important for cross-reactions. This cross-reactivity between papillomavirus types using polyclonal antisera is extensive. A commercially available antiserum which is raised against SDS-disrupted BPV-1 has been shown to detect HPV capsid antigens in tissue sections. We have shown (unpublished data) that the anti-BPV-1 antisera can detect both HPV-6-and -16-containing sections although positive cells were more easily identified using homologous polyclonal antisera since the reaction was stronger and the background lower. Other workers (Banks et al., 1987) have suggested that anti-BPV-1 antisera detect only HPV-6 L1 protein; however, they tested the cross-reactivity only on Western blots. We have further mapped the anti-BPV-1 cross-reactivity to a 15 amino acid region on the HPV-16 L1 protein (J. Cason et al., unpublished data) .
Antibodies raised against part of the minor capsid protein L2 appeared to have reduced crossreactivity since anti-L2/6 or anti-L2/16 did not recognize the L2 of HPV-1 and -2 in infected tissue sections. However, it was not possible to test the cross-reactivity of these antibodies to -infected tissues since in the homologous reaction very little L2 was detected in lesions. The tissue sections used were known to contain the Lt capsid protein. The low level of staining may be due to the small amounts of L2 produced or to disruption of epitopes following formaldehyde fixation.
For antibodies directed against the major capsid protein to be type-specific they must be monoclonal. We have produced monoclonal antibodies which detect only the HPV-16 L 1 fusion protein (L1/16) on Western blots and in HPV-16-infected biopsy sections. The monoclonal antibodies were able to detect HPV-I 6 in routine formaldehyde-fixed tissue and detected HPV-16 LI antigen in one-third of tissues which were positive with the polyclonal antisera. A large scale study is under way to assess the usefulness of these antibodies in routine diagnostic pathology.
These monoclonal antibodies have been used to map HPV-16-specific epitopes using overlapping peptides (J. Cason et al., unpublished data) with the aim of using HPV-16 peptides as target antigens to measure humoral response to HPV infection in patients. A serological screening test would be the most effective method of assessing HPV infection in patients and would enable population studies to be carried out to elucidate the role of HPV in genital cancers further. 
